Age at diagnosed (years) |
|
|
|
|
|
|
≤49 years |
18 (58.1%) |
18 (58.1%) |
17 (51.5%) |
17 (51.5%) |
0.599 |
0.599 |
>49 years |
13 (41.9%) |
13 (41.9%) |
16 (48.5%) |
16
(48.5%) |
|
|
BRCA-germline-mutation status |
|
|
|
|
|
|
BRCA1 mutation |
22 (71.0%) |
22 (71.0%) |
26 (78.8%) |
26 (78.8%) |
0.512 |
0.512 |
BRCA2 mutation |
8 (25.8%) |
8 (25.8%) |
7 (21.2%) |
7 (21.2%) |
|
|
Both BRCA1 and 2 mutations |
1 (3.2%) |
1 (3.2%) |
0 (0.0%) |
0
(0.0%) |
|
|
NAC-IDS |
|
|
|
|
|
|
Yes |
7 (22.6%) |
7 (22.6%) |
8 (24.2%) |
8 (24.2%) |
0.875 |
0.875 |
No |
24 (77.4%) |
24 (77.4%) |
25 (75.8%) |
25 (75.8%) |
|
|
FIGO stage at diagnosed |
|
|
|
|
|
|
I/II |
5 (16.1%) |
5 (16.1%) |
4 (12.1%) |
4 (12.1%) |
0.645 |
0.645 |
III/IV |
26 (83.9%) |
26 (83.9%) |
29 (87.9%) |
29 (87.9%) |
|
|
Primary tumor location |
|
|
|
|
|
|
Ovary |
30 (96.8%) |
30 (96.8%) |
32 (97.0%) |
32 (97.0%) |
0.964 |
0.964 |
Fallopian tube |
1 (3.2%) |
1 (3.2%) |
1 (3.0%) |
1 (3.0%) |
|
|
Histologic type |
|
|
|
|
|
|
High-grade serous |
30 (96.8%) |
30 (96.8%) |
30 (90.9%) |
30
(90.9%) |
0.268 |
0.268 |
Serous not specified |
0 (0.0%) |
0 (0.0%) |
2 (6.1%) |
2 (6.1%) |
|
|
Endometrioid |
1 (3.2%) |
1 (3.2%) |
0 (0.0%) |
0 (0.0%) |
|
|
Clear-cell |
0 (0.0%) |
0 (0.0%) |
1 (3.0%) |
1 (3.0%) |
|
|
Residual lesions |
|
|
|
|
|
|
No |
16 (51.6%) |
16 (51.6%) |
19 (57.6%) |
19 (57.6%) |
0.985 |
0.985 |
Yes |
10 (32.3%) |
10 (32.3%) |
12 (36.4%) |
12 (36.4%) |
|
|
Unknown a
|
5 (16.1%) |
5 (16.1%) |
2 (6.1%) |
2
(6.1%) |
|
|
PFI after 1st line of platinum-containing chemotherapy |
|
|
|
|
|
|
5-6months |
2 (6.5%) |
2 (6.5%) |
0 (0.0%) |
0 (0.0%) |
0.243 |
0.243 |
≥6, <12 months |
7 (22.6%) |
7 (22.6%) |
11 (33.3%) |
11
(33.3%) |
|
|
≥12 months |
22(71.0%) |
22(71.0%) |
22 (66.7%) |
22 (66.7%) |
|
|
PFI after 2nd line of platinum-containing chemotherapy |
|
|
|
|
|
|
≥6, <12 months |
23 (74.2%) |
23 (74.2%) |
21 (63.6%) |
21
(63.6%) |
0.363 |
0.363 |
≥12 months |
8 (25.8%) |
8 (25.8%) |
12 (36.4%) |
12 (36.4%) |
|
|
CA125 level at secondary platinum-sensitive relapse |
|
|
|
|
|
|
≤70 U/ml |
8 (25.8%) |
8 (25.8%) |
10 (30.3%) |
10 (30.3%) |
0.356 |
0.356 |
>70 U/ml |
23 (74.2%) |
23 (74.2%) |
17 (51.5%) |
17
(51.5%) |
|
|
Unknown a
|
0 (0.0%) |
0 (0.0%) |
6 (18.2%) |
6
(18.2%) |
|
|
Tumor response |
|
|
|
|
|
|
PR/CR |
24 (77.4%) |
24 (77.4%) |
21 (63.6%) |
21 (63.6%) |
0.538 |
0.538 |
SD/PD |
7 (22.6%) |
7 (22.6%) |
4 (12.1%) |
4 (12.1%) |
|
|
Unknown a
|
0 (0.0%) |
0 (0.0%) |
8 (24.2%) |
8
(24.2%) |
|
|
Duration of PARPi treatment |
Duration of PARPi treatment |
|
|
|
|
|
<6 months |
<6 months |
3 (9.7%) |
– |
– |
– |
– |
≥6, <12 months |
≥6, <12 months |
17 (54.8%) |
– |
– |
– |
|
≥12 months |
≥12 months |
11 (35.5%) |
– |
– |
– |
|
Hematological toxicity (≥ 3 CTCAE) |
Hematological toxicity (≥ 3 CTCAE) |
|
|
|
|
|
Yes |
Yes |
11 (35.5%) |
11 (35.5%) |
6 (18.2%) |
6 (18.2%) |
0.602 |
No |
No |
20 (64.5%) |
20 (64.5%) |
15 (45.5%) |
15 (45.5%) |
|
Unknown a
|
Unknown a
|
0 (0.0%) |
0 (0.0%) |
12 (36.4%) |
12 (36.4%) |
|